Final analysis of a phase I/IIa trial of the folate‐binding protein‐derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients
Autor: | Timothy J. Vreeland, Chad A. Hamilton, John S. Berry, Kathleen M. Darcy, George E. Peoples, Garth S. Herbert, Kevin Byrd, Jonathan W. Martin, Tommy A. Brown, Julia M. Greene, Diane F. Hale, George L. Maxwel, Guy T. Clifton, John W. Myers, Doreen O. Jackson, John C. Elkas, Thomas P. Conrads |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
Cancer Research medicine.medical_treatment Primary disease Gastroenterology FBP 0302 clinical medicine vaccine Prospective Studies Original Research Ovarian Neoplasms Folate Receptors GPI-Anchored Middle Aged Immunogenic peptide lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Treatment Outcome ovarian cancer Oncology 030220 oncology & carcinogenesis Vaccines Subunit endometrial cancer Female immunotherapy medicine.medical_specialty Immunization Secondary Cancer Vaccines lcsh:RC254-282 03 medical and health sciences Internal medicine HLA-A2 Antigen medicine Humans Radiology Nuclear Medicine and imaging Aged Dose-Response Relationship Drug business.industry Endometrial cancer E39 Granulocyte-Macrophage Colony-Stimulating Factor Clinical Cancer Research Immunotherapy medicine.disease Survival Analysis Folate-binding protein Endometrial Neoplasms 030104 developmental biology Landmark analysis Peptide vaccine Neoplasm Recurrence Local business Ovarian cancer |
Zdroj: | Cancer Medicine, Vol 8, Iss 10, Pp 4678-4687 (2019) Cancer Medicine |
ISSN: | 2045-7634 |
Popis: | Background E39, an HLA‐A2‐restricted, immunogenic peptide derived from the folate‐binding protein (FBP), is overexpressed in multiple malignancies. We conducted a phase I/IIa trial of the E39 + GM‐CSF vaccine with booster inoculations of either E39 or E39′ (an attenuated version of E39) to prevent recurrences in disease‐free endometrial and ovarian cancer patients(pts). Here, we present the final 24‐month landmark analysis. Patients and methods HLA‐A2 + patients receiving E39 + GM‐CSF were included in the vaccine group (VG), and HLA‐A2‐ pts (or HLA‐A2 + patients refusing vaccine) were followed as the control group (CG). VG group received 6 monthly inoculations as the primary vaccine series (PVS) and were randomized to receive either E39 or E39′ booster inoculations. Demographic, safety, immunologic, and disease‐free survival (DFS) data were collected and evaluated. Results Fifty‐one patients were enrolled; 29 in the VG and 22 in the CG. Fourteen patients received |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |